Glenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%
Deepthi | Myequity news | Date : 15-03-2019 10:18:00 IST
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin and Benzoyl Peroxide Gel, 1%|5%, a generic version of BenzaClin®1 Gel, 1%|5%, of Valeant Bermuda.
According to IQVIATM sales data for the 12 month period ending January 2019, the BenzaClin® Gel, 1%|5% market2 achieved annual sales of approximately $99.4 million*.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, immunology and pain.